Early Diagnosis Advisory Group (EDAG)

The Early Diagnosis Advisory Group (EDAG) is a policy-focused funding and advisory committee responsible for the oversight, development, review, and management of a portfolio of research that aims to significantly add to the evidence base that will impact on policy and practice for earlier cancer diagnosis.

Research areas

EDAG provides short-term project grants that use innovative, multidisciplinary and rapid approaches (using pre-existing data sources where necessary) to build the policy-related evidence base for earlier cancer diagnosis.

Applications for funding should be made in response to specific open calls for research advertised on the EDAG webpage.

The group does not fund biomedical research, such as the identification of biomarkers or new screening techniques, which should instead be directed to Population Research Committee.

How proposals are judged

The Committee meets up to three times a year for either strategic discussion or to assess funding applications. Applications are judged on the basis of scientific excellence, potential impact on policy and practice, strategic importance and also from the expert external peer review collated for each grant application.

 

Chair of EDAG

Prof Peter Sasieni - Queen Mary, University of London.

Vice-chair of EDAG

Prof Paul Aylin (Vice-chair) - Imperial College London

Dr Sally Vernon - Public Health England / National Cancer Registration Service

Dr Jo Waller - University College London

Dr Lilian Pittam - Patient representative

Dr Marjolein Berger - University Medical Center Groningen, The Netherlands

Mr John Butler - Royal Marsden Hospital, London

Prof Paul Little - University of Southampton

Mr Alan Chant - Patient representative

Dr Yoryos Lyratzopoulos – University College London

Dr Mick Peake - University Hospitals Leicester

Dr Gerry Richardson - University of York

Funded projects and outputs

Find out more about the research we fund

Browse EDAG projects and publications

Share this page